AGTC to host fourth quarter and end of fiscal 2021


GAINESVILLE, Fla. And CAMBRIDGE, Mass., September 16, 2021 (GLOBE NEWSWIRE) – Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of gene therapies based on adeno-associated viruses (AAV) for the treatment of rare inherited retinal diseases (RDI), today announced that it will release financial results for the quarter and fiscal year ended June 30, 2021 after market close on Thursday, September 23, 2021. AGTC management will host a conference call starting at 4:30 p.m. EST the same day to review the results and provide a company update.

To access the call, dial (844) 646-2697 (United States) or (918) 922-6902 (outside the United States). A live webcast will be available in the Events and Presentations section of the Investor Relations page at Please log in approximately 10 minutes before the scheduled start time. The archived webcast will be available in the Events & Presentations section of the company’s website.

About AGTC

AGTC is a clinical-stage biotechnology company that develops genetic therapies for people with rare and debilitating ophthalmic, otologic, and central nervous system (CNS) diseases. AGTC is a leader in the design and construction of all essential elements of gene therapy and in bringing them together to develop personalized therapies with the potential to meet the real needs of patients. AGTC’s most advanced clinical programs leverage its cutting-edge technology platform to potentially improve vision in patients with inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs draw on the Company’s cutting-edge AAV manufacturing technology and scientific expertise. AGTC is also advancing several important candidates to address the substantial unmet clinical needs in optogenetics, otology and CNS disorders, including entering into strategic partnerships with companies such as Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapies for neurotology; and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.


Jonathan nugent

Stern IR

T: 212-698-8698

[email protected]

Company contacts:

Stephen potter


Society of Applied Genetic Technologies

Phone. : (617) 413-2754

[email protected]

Source link


About Author

Leave A Reply